ter synthesis the protein is either stored within cytoplasmic organelles before secretion or released constitutively into plasma and the subendothelial matrix. vWF functions to stabilize factor VI11 and bridge platelets with exposed subendothelium at the site of vascular injury.5 Before its release from the cell of synthesis, the vWF protein undergoes a number of posttranslational modifications, including glycosylation, sulfation, and the formation of high molecular weight multimers.6 The protein circulates as multimers ranging in size from 400,000 to 20 million d a l t~n s .~'~ The clinical phenotype of vWD suggests significant pathogenetic heterogeneity. Types I and I11 vWD are characterized by quantitative abnormalities of vWF, whereas type I1 vWD is characterized by a qualitative abnormality with the consistent absence of high molecular weight multimeric forms of vWF from ~l a s m a .~ In type IIB vWD, plasma vWF shows a lack of the largest multimers, whereas platelet lysates show a normal multimeric profile." In addition, vWF synthesized in this disorder has been shown by a number of methods to possess an increased affinity for the platelet glycoprotein Ib
ON WILLEBRAND DISEASE (vWD) is the most
v common inherited bleeding disorder in humans.',' It results from quantitative or qualitative abnormalities in the plasma glycoprotein von Willebrand factor (vWF), which is synthesized in endothelial cells and megakaryocyte^.^.^ After synthesis the protein is either stored within cytoplasmic organelles before secretion or released constitutively into plasma and the subendothelial matrix. vWF functions to stabilize factor VI11 and bridge platelets with exposed subendothelium at the site of vascular injury.5 Before its release from the cell of synthesis, the vWF protein undergoes a number of posttranslational modifications, including glycosylation, sulfation, and the formation of high molecular weight multimers. 6 The protein circulates as multimers ranging in size from 400,000 to 20 million d a l t~n s .~'~ The clinical phenotype of vWD suggests significant pathogenetic heterogeneity. Types I and I11 vWD are characterized by quantitative abnormalities of vWF, whereas type I1 vWD is characterized by a qualitative abnormality with the consistent absence of high molecular weight multimeric forms of vWF from ~l a s m a .~ In type IIB vWD, plasma vWF shows a lack of the largest multimers, whereas platelet lysates show a normal multimeric profile." In addition, vWF synthesized in this disorder has been shown by a number of methods to possess an increased affinity for the platelet glycoprotein Ib
This property can result in platelet aggregation and the rapid clearance of these aggregates from the plasma, which in turn can result in intermittent Most cases of type IIB vWD described to date have been inherited as an autosomal-dominant trait. Rare recessive forms of the condition have also been reported." In addition, a disorder with similar clinical and laboratory features has been described-pseudo or platelet-type vWD-in which the abnormality lies in the platelet glycoprotein p r~f i l e .~~. '~ The cDNA sequence and genomic organization of the vWF gene have now been
The vWF gene spans approximately 178,000 bp and has 52 exons. The molecular abnormality resulting in type IIB vWD has yet to be defined, although a recent preliminary report has suggested that point mutations affecting the A1 domain of the protein may be responsible for the phenotype in at least one affected individ~al.'~ This study of three type IIB vWD families was performed to investigate the genetic linkage of this condition to the gene for vWF. In light of the complex posttranslational modification of this protein, a genetic defect at a site other than the vWF locus must be considered possible. We have used restriction fragment length polymorphisms (RFLPs) and a variable number tandem repeat (VNTR) polymorphism to investigate the segregation of the type IIB vWD phenotype with the gene for vWF.
MATERIALS AND METHODS

Materials.
Tris, sodium dodecyl sulphate (SDS), boric acid, sodium citrate, sodium chloride, magnesium chloride, phenol, butanol, chloroform, and polyacrylamide were obtained from BDH Inc (Toronto, Ontario, Canada). All reagents were analytical grade.
Ultrapure agarose, proteinase K, deoxyribonucleotide triphosphates (dNTPs), restriction endonucleases, and Taq polymerase were purchased from GIBCODRL (Burlington, Ontario, Canada). Gene Screen Plus hybridization membrane was from Dupont Canada Inc (Pointe Claire, Quebec, Canada). a-"P-dCTP was obtained from ICN Radiochemicals (Montreal, Quebec, Canada).
Three three-generation families (48 individuals) with type IIB vWD formed the basis for the study. Informed consent was obtained from all participating subjects and the study protocol had been approved by an ad hoc human ethics committee from the Faculty of Medicine, Queen's University, Kingston t+, Aggregation to 0.5 mg/mL ristocetin concentration; -, no aggregation below 1 mg/mL ristocetin concentration. *In contrast to the other members of this family, due to geographical constraints, these two individuals were tested on only one occasion. Their plasma samples arrived in our laboratory thawed; thus, the values for VIII:C may be artifactually low.
For personal use only. on October 23, 2017. by guest www.bloodjournal.org From BamHI RFLP (PIC 0.27),', and a 4-bp repeat vWF VNTR polymorphism in intron 40 of the vWF g e~~e . '~.~~ High molecular weight leukocyte DNA was obtained from individuals by standard techniques." Five micrograms DNA were digested to completion with the appropriate restriction endonucleases according to the manufacturer's instructions (GIBCOBRL). The digested DNA was electrophoresed on a 0.8% to 1.0% agarose gel at 50 V for 20 hours and capillary blotted to Gene Screen Plus nylon membrane?' Prehybridization was performed at 65°C overnight in 1.0 m o l t NaCI, 1% SDS, and 10% dextran sulphate. The membrane was hybridized with an a-"P-dCTP-labeled vWF probe overnight at 65°C and subsequently washed to a stringency of 0.1 x sodium chloride/ sodium citrate (SSC; 0.15 m o l t NaCl and 0.015 m o l t sodium citrate) and 0.1% SDS at 65°C for 30 minutes. Finally, the membrane was exposed to Kodak X A R J x-ray film (Rochester, NY) with an intensifying screen at -70°C for 1 to 7 days. Amplification was performed by PCR using an automated Perkin Elmer Cetus (Montreal, Quebec, Canada) DNA Thermal Cycler." Samples were amplified using a cycle of 1 minute at 94°C to denature, 2 minutes at 50°C to anneal primers, and 1.5 minutes at 72°C to extend. The procedure was repeated for 30 cycles. The resulting product was electrophoresed on a 12% polyacrylamide gel using a Tall Mighty Small electrophoresis unit (Hoefer Scientific, San Francisco, CA). Gels were stained with ethidium bromide and visualized under ultraviolet light. Endonuclease-digested pGEM plasmid was used for molecular weight estimation and three previously genotyped samples (demonstrating six different alleles) were included in each electrophoresis run.
Southem hybridization studies.
CATAGATATAGG-3.'9
RESULTS
The phenotypic coagulation profiles for the members of these families are shown in Table 1 .
Coagulation studies.
Variably normal or low values for Factor VIIIC, vwF:Ag, and vWFRiCof were demonstrated in all affected individuals and intermittent mild thrombocytopenia (50 to 100 x lo9/ L) was documented in most of these subjects. Hyperresponsiveness of affected subjects' platelets for ristocetininduced aggregation (ristocetin concentration 0.5 mg/mL) was evident in all patients tested. All patients demonstrated a type I1 vWD profile on analysis of plasma vWF multimers and/or crossed immunoelectrophoresis. Platelet lysate vWF multimers were normal in all the affected individuals tested. These results are all consistent with a diagnosis of type IIB vWD. Washed patient platelets did not aggregate in response to low-dose ristocetin when mixed with normal plasma, thus excluding the possibility of platelet-type vWD in these families."
RFLP studies. The five RFLPs and the vWF VNTR analyzed in this study are shown in Fig 1. The five conventional RFLPs are all biallelic systems, whereas the VNTR was found to have eight alleles comprising 6 to 14 repeats of the four-nucleotide repeat sequence (VNTR 6-14)?3 All six polymorphic sites are situated in the 3' half of the vWF gene.
The results of the family studies with these polymorphisms are shown in Fig 2. It can be seen that the type IIB phenotype cosegregates consistently with the vWF RFLP haplotype 1/2/1/1 in family 1. In families 2 and 3 only the VNTR polymorphism was informative.
In family 2, the VNTR allele 8 segregates with the vWD phenotype in the third generation. In the second generation, two affected subjects and seven unaffected individuals have inherited the VNTR 8 allele from the unaffected father (1.2). This raises the possibility of several potential phenomena, including gonadal mosaicism in the father, variable penetrance of the mutation, or the involvement of a locus other than the vWF gene in this kindred. In family 3, the analysis of individual 111.1 indicates cosegregation of the IIB phenotype with the VNTR 12 allele.
Although incomplete penetrance and variable expression of the phenotype is well described in type I vWD, there is no evidence of such phenomena in type I1 disease, where the biochemical defect is a distinct qualitative entity. Therefore, we propose that the findings in family 2 are best explained by the presence of gonadal mosaicism in the firstgeneration male, and that if this assumption is correct, we can conclude that these families showed cosegregation of the type IIB vWD phenotype to the gene for vWF with a combined logarithm of the odds ratio (LOD score) of 7.2 (0 = O.O), indicating greater than 10 million to 1 odds in favor of linkage. Even if the results from family 2 are considered to be the consequence of several recombination events in the second generation, the maximum LOD score (2.25 at 0 = 0.14) is still more in favor of linkage to either the vWF gene itself or an adjacent locus, rather than a distant site on the genome. These results provide further independent support for the hypothesis concerning the existence of germline mosaicism in the first-generation male.
For personal use only. on October 23, 2017. by guest www.bloodjournal.org From In light of the complex posttranslational processing of this molecule, there has been speculation as to whether the underlying genetic defect in these conditions is consistently in the vWF gene itself or at an alternative genetic locus involved in these modifying events. In types I and 111 vWD, where a similar diversity of disease is evident, this issue has been addressed by the observation of vWF gene deletions in some type 111 patient^^'.^' and the cosegregation of vWF RFLPs with types I and'III vWD in a small number of fa mi lie^.^^'^^.^' Similarly, a study using two vWF RFLPs in one large type IIA vWD kindred demonstrated complete linkage of this phenotype with the vWF gene locus (LOD score 5.88)." Recently two
We investigated the genetic linkage of type IIBvWD with the gene for vWF in three families. Using six intragenic polymorphic markers, we have demonstrated that type IIB vWD is linked to the gene for vWF with a significant LOD score of 7.2, assuming that our hypothesis concerning the presence of germline mosaicism in family 2 is correct. Probing with cDNA probes from both ends of the vWF gene has indicated that large deletions, insertions, or rearrangements are unlikely as the cause for vWD in these families. In one of these families we identified a pattern of disease inheritance that, if the disease is linked to the gene for vWF, is consistent with gonadal mosaicism.
vWD is characterized by marked variability in its clinical manifestations and laboratory phenotype4' all of which suggests that there is likely an underlying mutational heterogeneity. The type I1 forms of vWD are all characterized by the absence from plasma of the hemostatically important large molecular weight multimers.' Patients with type IIB vWD synthesize a form of vWF that has an increased affinity for the platelet glycoprotein Ib recep- 
